Top-News

BeOne Medicines Aktie (ADR) News

Aktie
WKN:  A1437N ISIN:  US07725L1026 US-Symbol:  ONC Branche:  Biotechnologie Land:  Schweiz
316,66 $
-14,74 $
-4,45%
271,94 € 16:51:23 Uhr
Depot/Watchlist
Marktkapitalisierung *
34,37 Mrd. €
Streubesitz
46,59%
KGV
-30,43
Faktor
0.0769231
Originalaktie
CH1391448177

BeOne Medicines Aktie (ADR) News

08.07.25 - PR Newswire
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention PR Newswire
08.07.25 - PR Newswire
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention PR Newswire
08.07.25 - PR Newswire
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-​Enabling Studies PR Newswire
30.06.25 - PR Newswire
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch PR Newswire
30.06.25 - PR Newswire
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch PR Newswire
30.06.25 - PR Newswire
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy PR Newswire
26.06.25 - PR Newswire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? PR Newswire
26.06.25 - PR Newswire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? PR Newswire
24.06.25 - PR Newswire
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices PR Newswire
24.06.25 - PR Newswire
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices PR Newswire
20.06.25 - PR Newswire
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology PR Newswire
20.06.25 - PR Newswire
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology PR Newswire
18.06.25 - PR Newswire
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going PR Newswire
18.06.25 - PR Newswire
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going PR Newswire
12.06.25 - PR Newswire
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry PR Newswire
12.06.25 - PR Newswire
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry PR Newswire
12.06.25 - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation
After Major Oncology Conference, All Eyes Turn to Industry Innovation PR Newswire
12.06.25 - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation
After Major Oncology Conference, All Eyes Turn to Industry Innovation PR Newswire
11.06.25 - PR Newswire
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs PR Newswire
23.05.25 - PR Newswire
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs
New Data and Deal Flow Signal a Turning Point for Precision-​Driven Cancer Biotechs PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +2,17%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »